CL2004000498A1 - Polimorfo alpha, beta, gamma de rifaximina; procesos para la preparacion de dichos polimorfos; composicion farmaceutica que comprende dichos polimorfos, utiles como antibacterianos. - Google Patents

Polimorfo alpha, beta, gamma de rifaximina; procesos para la preparacion de dichos polimorfos; composicion farmaceutica que comprende dichos polimorfos, utiles como antibacterianos.

Info

Publication number
CL2004000498A1
CL2004000498A1 CL200400498A CL2004000498A CL2004000498A1 CL 2004000498 A1 CL2004000498 A1 CL 2004000498A1 CL 200400498 A CL200400498 A CL 200400498A CL 2004000498 A CL2004000498 A CL 2004000498A CL 2004000498 A1 CL2004000498 A1 CL 2004000498A1
Authority
CL
Chile
Prior art keywords
polymorphes
useful
rifaximina
rifaxymin
antibacterial
Prior art date
Application number
CL200400498A
Other languages
English (en)
Inventor
Giuseppe C. Viscomi
Manuela Campana
Dario Braga
Donatella Confortini
Vincenzo Cannata
Denis Severini
Paolo Righi
Goffredo Rosini
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33187382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2004000498(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Publication of CL2004000498A1 publication Critical patent/CL2004000498A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12—Cooking devices
    • H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1236—Cooking devices induction cooking plates or the like and devices to be used in combination with them adapted to induce current in a coil to supply power to a device and electrical heating devices powered in this way
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12—Cooking devices
    • H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1245—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements
    • H05B6/1263—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements using coil cooling arrangements

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Electromagnetism (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

FOMAS CRISTALINAS DEL ANTOBIOTICO RIFAXIMINA (INN) DENOMINADAS RIFAXIMINA a Y RIFAXIMINA b Y UNA FORMA POBREMENTE CRIATALINA DENOMINADA RIFAXIMINA y. ESTAS FORMAS SON DE UTILIDAD EN LA PRODUCCION DE PREPARACIONES MEDICINALES PARA USO POR VIA ORAL Y TOPICA Y SE PUEDE OBTENER POR MEDIO DE UN PROCESO DE CRISTALIZACION LLEVADO A CABO POR DISOLUCION EN CALIENTE DE LA RIFAXIMINA CRUDA EN ALCOHOL ETILICO Y POR CRISTALIZACION DEL PRODUCTO MEDIANTE LA ADICION DE AGUA A UNA TEMPERATURA DETERMINADA Y POR UN PERIODO DE TIEMPO DETERMINADO. LA CRISTALIZACION ES SEGUIDA DE UN SECADO LLVADO ACABO BAJO CONDICIONES CONTROLADAS HASTA ALCANZAR UN CONTENIDO DE AGUA ESPECIFICO EN EL PRODUCTO FINAL.
CL200400498A 2003-11-07 2004-03-11 Polimorfo alpha, beta, gamma de rifaximina; procesos para la preparacion de dichos polimorfos; composicion farmaceutica que comprende dichos polimorfos, utiles como antibacterianos. CL2004000498A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT002144A ITMI20032144A1 (it) 2003-11-07 2003-11-07 Forme polimorfe di rifaximina, processi per ottenerle e

Publications (1)

Publication Number Publication Date
CL2004000498A1 true CL2004000498A1 (es) 2005-03-11

Family

ID=33187382

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200400498A CL2004000498A1 (es) 2003-11-07 2004-03-11 Polimorfo alpha, beta, gamma de rifaximina; procesos para la preparacion de dichos polimorfos; composicion farmaceutica que comprende dichos polimorfos, utiles como antibacterianos.

Country Status (37)

Country Link
US (5) US7045620B2 (es)
EP (6) EP1676847B1 (es)
JP (5) JP2005139161A (es)
KR (4) KR20050043589A (es)
CN (4) CN1613858A (es)
AR (3) AR043547A1 (es)
AT (3) ATE361927T1 (es)
AU (2) AU2004200964A1 (es)
BR (2) BRPI0402382A (es)
CA (2) CA2460384A1 (es)
CL (1) CL2004000498A1 (es)
CO (1) CO5560083A1 (es)
CY (3) CY1108017T1 (es)
DE (4) DE602004019296D1 (es)
DK (3) DK1557421T3 (es)
ES (3) ES2244364T3 (es)
HR (2) HRP20040265A2 (es)
IL (2) IL160798A0 (es)
IT (1) ITMI20032144A1 (es)
JO (1) JO2470B1 (es)
MA (1) MA27069A1 (es)
MD (1) MD3653G8 (es)
ME (1) ME00424B (es)
MX (2) MXPA04002353A (es)
NO (1) NO334950B1 (es)
NZ (1) NZ531622A (es)
PL (3) PL1557421T3 (es)
PT (3) PT1557421E (es)
RS (4) RS54571B1 (es)
RU (1) RU2270200C2 (es)
SI (3) SI1676848T1 (es)
TN (2) TNSN04044A1 (es)
TW (1) TWI285107B (es)
UA (1) UA86384C2 (es)
WO (1) WO2005044823A2 (es)
YU (1) YU24804A (es)
ZA (1) ZA200401948B (es)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7923553B2 (en) * 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US7906542B2 (en) * 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US20080262024A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
SI1698630T1 (sl) 2005-03-03 2015-01-30 Alfa Wassermann S.P.A. Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
JP5844961B2 (ja) 2006-08-02 2016-01-20 サリックス ファーマシューティカルズ， インコーポレイテッド 放射線直腸ｓ状結腸炎を処置するための組成物および方法
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
EP2069363B1 (en) * 2006-09-22 2013-03-20 Cipla Ltd. Rifaximin in an amorphous form
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
AU2008273699A1 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
AU2016203925B2 (en) * 2007-07-06 2016-10-20 Lupin Limited Pharmaceutical compositions of rifaximin
EP2420226B1 (en) * 2007-07-06 2020-03-04 Lupin Limited Pharmaceutical compositions of rifaximin
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
WO2009108730A2 (en) * 2008-02-25 2009-09-03 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
ES2727728T3 (es) 2008-02-26 2019-10-18 Salix Pharmaceuticals Ltd Métodos para el tratamiento del síndrome del intestino irritable
US11779571B2 (en) * 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
PL2294012T3 (pl) 2008-05-07 2014-12-31 Salix Pharmaceuticals Inc Podawanie środka czyszczącego jelito i antybiotyku w leczeniu choroby jelit
DK2327407T3 (da) 2008-09-26 2014-08-25 Aska Pharm Co Ltd Profylaktisk og/eller terapeutisk middel til funktionelle gastrointestinale sygdomme
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US20100317681A1 (en) * 2009-06-15 2010-12-16 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
SMT202400116T1 (it) * 2008-10-02 2024-05-14 Salix Pharmaceuticals Ltd Trattamento dell’encefalopatia epatica utilizzando rifaximina
US8916193B2 (en) 2008-12-10 2014-12-23 Cipla Limited Rifaximin complexes
IT1397617B1 (it) * 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
BRPI1010028A2 (pt) 2009-06-02 2019-02-12 Salix Pharmaceuticals, Ltd. métodos de tratamento de encefalopatia hepática
WO2011032085A1 (en) 2009-09-13 2011-03-17 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome (ibs)
WO2011051971A2 (en) * 2009-10-27 2011-05-05 Lupin Limited Solid dispersion of rifaximin
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
RU2012126084A (ru) 2009-11-23 2013-12-27 Сипла Лимитед Пенная композиция для местного применения
US8952159B2 (en) 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
JP5896380B2 (ja) 2010-02-18 2016-03-30 サリックス ファーマスーティカルズ，リミテッド 感染症を治療するための方法
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
CA2800668A1 (en) * 2010-06-03 2011-12-08 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
EP2582707A4 (en) * 2010-06-16 2014-01-08 Apotex Pharmachem Inc POLYMORPHIC FORMS OF RIFAXIMINE
HUE049986T2 (hu) * 2010-07-12 2020-11-30 Salix Pharmaceuticals Inc Rifaximin készítmények és ezek alkalmazásai
WO2012035544A2 (en) 2010-09-13 2012-03-22 Sequent Scientific Ltd. A novel polymorphic form of rifaximin and process for its preparation
IT1403847B1 (it) * 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012060675A1 (es) * 2010-11-05 2012-05-10 Interquim, S.A. De C.V. Proceso para la preparación de rifaximina amorfa
WO2012076832A1 (en) * 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
WO2012109605A2 (en) 2011-02-11 2012-08-16 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
AU2012251385A1 (en) 2011-05-02 2013-11-21 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
WO2012155981A1 (en) 2011-05-19 2012-11-22 Friulchem Spa New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
ITMI20110890A1 (it) * 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
EP2773205B1 (en) 2011-11-02 2024-05-22 Salix Pharmaceuticals, Inc. Rifaximin for retreating diarrhea-predominant irritable bowel syndrome
JP2013184902A (ja) * 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
WO2013185211A1 (en) * 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
WO2014091432A1 (en) 2012-12-12 2014-06-19 Ranbaxy Laboratories Limited Pharmaceutical compositions of rifaximin
JP2016516988A (ja) 2013-03-15 2016-06-09 アルファ ワッセルマン ソシエタ ペル アチオニＡｌｆａ Ｗａｓｓｅｒｍａｎｎ Ｓ．Ｐ．Ａ． 膣感染症を診断するための方法
EA201591267A1 (ru) 2013-03-15 2016-03-31 Альфа Вассерманн С.П.А. Рифаксимин для применения в лечении вагинальных инфекций
AU2014252219B2 (en) 2013-04-12 2018-11-22 Alfasigma S.P.A. NSAID administration and related compositions, methods and systems.
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
WO2015159275A2 (en) * 2014-04-19 2015-10-22 Granules India Limited An improved process for the preparation of rifamycin derivatives
MX375805B (es) 2014-05-04 2025-03-07 Salix Pharmaceuticals Inc Microbiota ibs y sus usos.
PT3546464T (pt) 2014-05-12 2020-08-05 Alfasigma Spa Preparação e utilização da forma cristalina tau de rifaximina solvatada com degme
CN106999477B (zh) * 2014-06-30 2020-04-10 萨利克斯药品公司 用于重复治疗肠易激综合征(ibs)的方法
CN104083324B (zh) * 2014-07-10 2017-05-10 青岛动保国家工程技术研究中心有限公司 一种利福昔明的兽用悬乳剂及其制备方法和应用
EP2982764A1 (en) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identification of vaginal bacteria
CN104274391B (zh) * 2014-10-08 2017-02-01 哈尔滨坤盟医药科技有限公司 一种含利福昔明的药物制剂
WO2017021975A1 (en) * 2015-08-06 2017-02-09 Msn Laboratories Private Limited Process for the preparation of crystalline forms of rifaximin
TR201909029T4 (tr) 2016-03-24 2019-07-22 Sandoz Ag Rifaksimin alfa içeren saklanmaya yönelik kararlı bileşimler.
US10576065B2 (en) 2016-03-24 2020-03-03 Sandoz Ag Pharmaceutical composition containing rifaximin alpha and delta
US9988398B2 (en) * 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
PL3518924T3 (pl) 2016-09-30 2023-01-09 Salix Pharmaceuticals, Inc. Postacie stałej dyspersji ryfaksyminy
CN106632396B (zh) * 2017-01-06 2019-01-11 成都樵枫科技发展有限公司 γ晶型利福昔明的制备方法和用途
PL3416627T3 (pl) 2017-04-26 2020-06-01 Sandoz Ag Doustna postać dawkowania zawierająca rifaksyminę w postaci beta
HUE054832T2 (hu) 2017-06-26 2021-10-28 Biofer Spa Pirido-imidazo rifamicinszármazékok baktériumellenes szerként
US20220062183A1 (en) * 2018-12-19 2022-03-03 Friulchem S.P.A. Process for the manufacture of a tablet of rifaximin and tablet of rifaximin
WO2020245214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
AU2020355603B2 (en) 2019-09-24 2026-02-12 Bausch Health Ireland Limited Rifaximin liquid formulations
WO2021191312A1 (en) 2020-03-24 2021-09-30 Bausch Health Ireland Limited Methods of treating covid-19 with rifaximin
WO2021229480A1 (en) * 2020-05-15 2021-11-18 Atra Pharmaceuticals Limited Polymorph of rifaximin, process for the preparation thereof and pharmaceutical composition containing rifaximin
CN116018133A (zh) 2020-06-26 2023-04-25 博士医疗爱尔兰有限公司 靶向释放利福昔明组合物
US20230398102A1 (en) 2020-10-29 2023-12-14 Bausch Health Ireland Limited Rifaximin liquid formulations for use inthe treatment of sickle cell disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241785A (en) * 1978-07-24 1980-12-30 Peerless Of America, Inc. Heat exchangers and method of making same
IT1154655B (it) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
CA1215976A (en) 1984-05-15 1986-12-30 Vincenzo Cannata New process for the synthesis of imidazo rifamycins
IT1199374B (it) * 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
IT1199413B (it) 1984-09-26 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
GB8816620D0 (en) * 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
KR0170000B1 (ko) * 1990-06-29 1999-02-01 레나토 스가르비 순수한 결정 형태의 리파펜틴
SK9742002A3 (en) * 2000-01-07 2003-02-04 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
AU1234002A (en) * 2000-10-31 2002-05-15 Ciba Sc Holding Ag Crystalline forms of venlafaxine hydrochloride
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20050262269A1 (en) 2004-05-20 2005-11-24 Pike Jimmy D System and method for information handling system PCI express advanced switching
SI1698630T1 (sl) 2005-03-03 2015-01-30 Alfa Wassermann S.P.A. Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
EP2069363B1 (en) 2006-09-22 2013-03-20 Cipla Ltd. Rifaximin in an amorphous form
WO2008115572A1 (en) 2007-03-21 2008-09-25 Theraquest Biosciences, Inc. Methods and compositions of nsaids
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
AU2008273699A1 (en) 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
EP2420226B1 (en) 2007-07-06 2020-03-04 Lupin Limited Pharmaceutical compositions of rifaximin
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
JP2011500552A (ja) 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
WO2009108730A2 (en) 2008-02-25 2009-09-03 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof

Also Published As

Publication number Publication date
KR100855084B1 (ko) 2008-08-29
MD3653F2 (en) 2008-07-31
CN101260114B (zh) 2012-11-28
US20110160449A1 (en) 2011-06-30
EP2208730A1 (en) 2010-07-21
ES2320160T3 (es) 2009-05-19
HRP20040265A2 (en) 2004-12-31
CN1886408A (zh) 2006-12-27
ES2320161T3 (es) 2009-05-19
CA2460384A1 (en) 2005-05-07
CN1886408B (zh) 2010-06-09
SI1676848T1 (sl) 2009-06-30
DE602004019296D1 (de) 2009-03-19
UA86384C2 (uk) 2009-04-27
CN101260114A (zh) 2008-09-10
AR081991A2 (es) 2012-10-31
JP2011046738A (ja) 2011-03-10
AU2004287601B2 (en) 2009-02-26
MXPA04002353A (es) 2005-05-11
EP1676848A1 (en) 2006-07-05
AU2004287601B8 (en) 2009-03-05
JO2470B1 (en) 2009-01-20
CY1108909T1 (el) 2014-07-02
MXPA06002644A (es) 2006-06-06
IL174271A0 (en) 2006-08-01
RU2004108953A (ru) 2005-10-27
EP1676848B1 (en) 2009-01-28
PL1676847T3 (pl) 2009-07-31
CA2538546A1 (en) 2005-05-19
PL1557421T3 (pl) 2007-08-31
DK1557421T3 (da) 2007-09-17
NO20061110L (no) 2006-04-19
PT1557421E (pt) 2007-07-31
CO5560083A1 (es) 2005-09-30
ITMI20032144A1 (it) 2005-05-08
PL1676848T3 (pl) 2009-07-31
IL174271A (en) 2010-12-30
DE602004006367D1 (de) 2007-06-21
KR20060110737A (ko) 2006-10-25
EP1557421A1 (en) 2005-07-27
DE602004019298D1 (de) 2009-03-19
EP1557421B1 (en) 2007-05-09
JP5199576B2 (ja) 2013-05-15
HRP20060093B1 (hr) 2015-12-18
CN101260115A (zh) 2008-09-10
WO2005044823A2 (en) 2005-05-19
SI1676847T1 (sl) 2009-06-30
CN1613858A (zh) 2005-05-11
RS20150291A1 (sr) 2015-10-30
KR20070113326A (ko) 2007-11-28
EP1682556A2 (en) 2006-07-26
HK1073657A1 (en) 2005-10-14
KR20050043589A (ko) 2005-05-11
AR043547A1 (es) 2005-08-03
TNSN06069A1 (en) 2007-10-03
ES2244364T1 (es) 2005-12-16
US8173801B2 (en) 2012-05-08
BRPI0407149A8 (pt) 2019-01-15
DK1676847T3 (da) 2009-05-11
RS20150292A1 (sr) 2015-10-30
TNSN04044A1 (en) 2006-06-01
NO334950B1 (no) 2014-08-04
ES2244364T3 (es) 2007-12-01
BRPI0407149A (pt) 2006-02-07
US7915275B2 (en) 2011-03-29
US20050101598A1 (en) 2005-05-12
AU2004200964A1 (en) 2005-05-26
DE602004006367T2 (de) 2007-09-06
EP1676847A1 (en) 2006-07-05
KR100883216B1 (ko) 2009-02-13
CA2538546C (en) 2011-04-19
US20050272754A1 (en) 2005-12-08
IL160798A0 (en) 2004-08-31
ES2320160T4 (es) 2011-03-09
WO2005044823A3 (en) 2005-10-27
PT1676847E (pt) 2009-04-09
US8404704B2 (en) 2013-03-26
AR081992A2 (es) 2012-10-31
SI1557421T1 (sl) 2007-08-31
DE04005541T1 (de) 2005-12-29
RS54568B1 (sr) 2016-06-30
NZ531622A (en) 2004-10-29
RU2270200C2 (ru) 2006-02-20
RS20060168A (sr) 2008-09-29
MD3653G8 (ro) 2016-08-31
CN101260115B (zh) 2011-11-23
YU24804A (sh) 2006-08-17
JP5635376B2 (ja) 2014-12-03
ATE421966T1 (de) 2009-02-15
JP2014177500A (ja) 2014-09-25
JP2011057698A (ja) 2011-03-24
JP2007509904A (ja) 2007-04-19
RS54569B1 (sr) 2016-06-30
CY1108017T1 (el) 2013-09-04
ATE361927T1 (de) 2007-06-15
EP2210893A1 (en) 2010-07-28
BRPI0402382A (pt) 2005-06-28
MA27069A1 (fr) 2004-12-20
AU2004287601A1 (en) 2005-05-19
US20080132530A1 (en) 2008-06-05
HK1092150A1 (en) 2007-02-02
DK1676848T3 (da) 2009-05-11
JP2005139161A (ja) 2005-06-02
US20120059023A1 (en) 2012-03-08
ZA200401948B (en) 2004-04-29
CY1108964T1 (el) 2014-07-02
KR20070113327A (ko) 2007-11-28
HK1092151A1 (en) 2007-02-02
PT1676848E (pt) 2009-04-09
EP1676847B1 (en) 2009-01-28
TWI285107B (en) 2007-08-11
MD20060080A (en) 2006-11-30
US7045620B2 (en) 2006-05-16
HRP20060093A2 (en) 2006-05-31
ATE421965T1 (de) 2009-02-15
TW200515913A (en) 2005-05-16
RS54571B1 (sr) 2016-06-30
ME00424B (me) 2011-10-10
DE602004006367C5 (de) 2019-04-04
KR100867751B1 (ko) 2008-11-10

Similar Documents

Publication Publication Date Title
TW200515913A (en) Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations
AR106561A2 (es) Composición farmacéutica que contiene un ácido tetrahidrofólico
ECSP099451A (es) Compuestos de urea policíclicos antibacterianos
CO6290656A2 (es) Derivados heterociclicos de urea y metodos de uso de los mismos -211
UY29384A1 (es) Derivados del ácido2-3s,4r)-4-(((3,4-dicloro-5-metil-1h-pirrol-2-il) carbonil)amino)-1,3-tiazol-5-carboxílico y sus sales, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciónes.
GT199900203A (es) Composiciones de celecoxib.
ECSP088859A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
HRP20130026T1 (hr) Kristalni oblik posakonazola
BRPI0715853B8 (pt) uso de polióis contendo pelo menos dois grupos hidróxi para estabilizar formas polimorfas da rifaximina, rifaximina beta, suas preparações medicinais, seus microgrânulos e seu processo de preparação
UY32598A (es) Sal de abt-263 y formas en estado sólido de la misma
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.
PA8801901A1 (es) Suspension pediatrica estabilizada de carisbamato
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
UY31864A (es) Derivados de urea hetericíclica y métodos de uso de los mismos-332
UY32856A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
DE60316152D1 (de) Prozess zur herstellung von pioglitazon via verschiedene zwischenstufen
UY30121A1 (es) Nuevos compuestos
UY32694A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
MY148124A (en) Preparation of a crystalline antibiotic substance
EP4026566C0 (en) ORAL PHARMACEUTICAL COMPOSITION COMPRISING TERIPARATIDE AND PROCESS FOR ITS PREPARATION
CL2007003009A1 (es) N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)piperidin-4-ilideno)metil)benzamida; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento del dolor, ansiedad y depresion.
ATE435864T1 (de) Substituierte 5,6,7,8-tetrahydro-imidazoä1 ,2- aüpyridin-2-ylamin-verbindungen und deren verwendung zur herstellung von arzneimitteln
CL2012000478A1 (es) Formas cristalinas de 4,5,6,7-tetrahidro-11-metoxi-2-[(4-metil-1-piperazinil)metil]-1h-ciclopenta[alfa]pirrolo[3,4-c]carbazol-1,3(2h)-diona; composicion farmaceutica; y uso en el tratamiento de cancer.
UY26211A1 (es) Polimorfos de un diclorhidrato cristalino de azobiciclo (2.2.2)oct-3-ilamina y sus composiciones farmaceuticas
CO2019000513A2 (es) Formas cristalinas de un compuesto de tetraciclina sustituido con 9-aminometilo y un método de preparación de las mismas